Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)

Overview

Journal Gut Liver

Specialty Gastroenterology

Date 2015 Sep 9

PMID 26347512

Citations 11

Authors

Eun Soo Kim

Kyeong Ok Kim

Byung Ik Jang

Chang Kyun Lee

Hyo Jong Kim

Kang-Moon Lee

You Sun Kim

Chang Soo Eun

Sung-Ae Jung

Suk-Kyun Yang

Jun Lee

Tae-Oh Kim

Yunho Jung

Geom Seog Seo

Soon Man Yoon

Affiliations

Soon will be listed here.

Abstract

Background/aims: Two comparable anti-tumor necrosis factor (TNF) agents with different routes of administration (intravenous [iv] infliximab [IFX] vs subcutaneous [sc] adalimumab [ADA]) are available for patients with Crohn's disease (CD) in Korea. This study aimed to identify the preferences of Korean CD patients for a specific anti-TNF agent and the factors contributing to the decision.

Methods: A prospective survey was performed among anti-TNF-naive CD patients in 10 tertiary referral hospitals. A 16-item questionnaire addressed patient preferences and the factors contributing to the decision in favor of a particular anti-TNF agent. A logistic regression was conducted to assess predictive factors for ADA preference.

Results: Overall, 189 patients (139 males; mean age, 32.47±11.71 years) completed the questionnaire. IFX and ADA were preferred by 63.5% (120/189) and 36.5% (69/189) of patients, respectively. The most influential reason for choosing IFX was 'doctor's presence' (68.3%, 82/120), and ADA was "easy to use" (34.8%, 24/69). Amid various clinicodemographic data, having a >60-minute travel time to the hospital was a significant independent predictive factor for ADA preference.

Conclusions: A large number of anti-TNF-naive Korean patients with CD preferred anti-TNFs with an iv route of administration. The reassuring effect of a doctor's presence might be the main contributing factor for this decision.

Citing Articles

Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure.

Bae J, Park J, Baek J, Hong S, Park S, Yang D Gut Liver. 2024; 18(4):667-676.

PMID: 38835325 PMC: 11249938. DOI: 10.5009/gnl230291.

Infliximab adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn's disease.

Kim E, Kang B World J Gastroenterol. 2023; 29(18):2784-2797.

PMID: 37274072 PMC: 10237103. DOI: 10.3748/wjg.v29.i18.2784.

What are the Unmet Needs and Most Relevant Treatment Outcomes According to Patients with Inflammatory Bowel Disease? A Qualitative Patient Preference Study.

Schoefs E, Vermeire S, Ferrante M, Sabino J, Lambrechts T, Avedano L J Crohns Colitis. 2022; 17(3):379-388.

PMID: 36165579 PMC: 10069611. DOI: 10.1093/ecco-jcc/jjac145.

Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study.

Han M, Jung Y, Cheon J, Park S Yonsei Med J. 2019; 61(1):48-55.

PMID: 31887799 PMC: 6938779. DOI: 10.3349/ymj.2020.61.1.48.

Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.

Jung Y, Han M, Park S, Cheon J Dig Dis Sci. 2019; 65(5):1436-1444.

PMID: 31677070 DOI: 10.1007/s10620-019-05867-1.

References

Choi C, Kim Y, Kim Y, Ye B, Lee K, Lee B . [Guidelines for the management of ulcerative colitis]. Korean J Gastroenterol. 2012; 59(2):118-40. DOI: 10.4166/kjg.2012.59.2.118. View

Constantinescu F, Goucher S, Weinstein A, Smith W, Fraenkel L . Understanding why rheumatoid arthritis patient treatment preferences differ by race. Arthritis Rheum. 2009; 61(4):413-8. PMC: 4062353. DOI: 10.1002/art.24338. View

Hanauer S, Feagan B, Lichtenstein G, Mayer L, Schreiber S, Colombel J . Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359(9317):1541-9. DOI: 10.1016/S0140-6736(02)08512-4. View

Chang C, Wei S, Chou J, Hsu T, Chuang C, Lin C . Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study. Intest Res. 2014; 12(4):287-92. PMC: 4214955. DOI: 10.5217/ir.2014.12.4.287. View

Kim N, Jung Y, Moon C, Lee S, Ran Kim E, Kim Y . Long-term clinical outcomes of korean patient with Crohn's disease following early use of infliximab. Intest Res. 2014; 12(4):281-6. PMC: 4214954. DOI: 10.5217/ir.2014.12.4.281. View

Ye B, Jang B, Jeen Y, Lee K, Kim J, Yang S . [Diagnostic guideline of Crohn's disease]. Korean J Gastroenterol. 2009; 53(3):161-76. View

Williams E, Edwards C . Patient preferences in choosing anti-TNF therapies-R1. Rheumatology (Oxford). 2006; 45(12):1575-6. DOI: 10.1093/rheumatology/kel369. View

Nisbett R, Peng K, Choi I, Norenzayan A . Culture and systems of thought: holistic versus analytic cognition. Psychol Rev. 2001; 108(2):291-310. DOI: 10.1037/0033-295x.108.2.291. View

Lobaton T, Vermeire S, Van Assche G, Rutgeerts P . Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2014; 39(6):579-94. DOI: 10.1111/apt.12639. View

10.

Hanauer S, Sandborn W, Rutgeerts P, Fedorak R, Lukas M, MacIntosh D . Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006; 130(2):323-33. DOI: 10.1053/j.gastro.2005.11.030. View

11.

Colombel J, Sandborn W, Rutgeerts P, Enns R, Hanauer S, Panaccione R . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132(1):52-65. DOI: 10.1053/j.gastro.2006.11.041. View

12.

Silliman R, Dukes K, Sullivan L, Kaplan S . Breast cancer care in older women: sources of information, social support, and emotional health outcomes. Cancer. 1998; 83(4):706-11. View

13.

Lee K, Lee J . Crohn's disease in Korea: past, present, and future. Korean J Intern Med. 2014; 29(5):558-70. PMC: 4164717. DOI: 10.3904/kjim.2014.29.5.558. View

14.

Vavricka S, Bentele N, Scharl M, Rogler G, Zeitz J, Frei P . Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). Inflamm Bowel Dis. 2011; 18(8):1523-30. DOI: 10.1002/ibd.21888. View

15.

Van Assche G, Vermeire S, Rutgeerts P . Mucosal healing and anti TNFs in IBD. Curr Drug Targets. 2010; 11(2):227-33. DOI: 10.2174/138945010790309902. View

16.

Yang S, Yun S, Kim J, Park J, Kim H, Kim Y . Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis. 2007; 14(4):542-9. DOI: 10.1002/ibd.20310. View

17.

Kitayama S, Karasawa M, Curhan K, Ryff C, Markus H . Independence and interdependence predict health and wellbeing: divergent patterns in the United States and Japan. Front Psychol. 2011; 1:163. PMC: 3153777. DOI: 10.3389/fpsyg.2010.00163. View

18.

Chilton F, Collett R . Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care. 2007; 6(1):1-14. DOI: 10.1002/msc.110. View

19.

Rutgeerts P, DHaens G, Targan S, Vasiliauskas E, Hanauer S, Present D . Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999; 117(4):761-9. DOI: 10.1016/s0016-5085(99)70332-x. View

20.

Scharl M, Vavricka S, Rogler G . Review: new anti-cytokines for IBD: what is in the pipeline?. Curr Drug Targets. 2013; 14(12):1405-20. DOI: 10.2174/13894501113149990159. View